|
|
 | | | |
- close
- close
- close
- close
Corcept Therapeutics (CORT) |
Benzinga
May 6
Comment
In a report published Monday, Piper Jaffray analyst Charles C. Duncan downgraded the rating on Corcept Therapeutics (NASDAQ: CORT) from Overweight to Neutral, and lowered the price target from $4.00 to $2.00.
In the report, Duncan noted,...
StreetInsider.com
Mar 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Corcept+Therapeutics%2C+Inc.+%28CORT%29+Reports+In-Line+Q4+Loss+of+9cShare/8167758.html for the full story.
FierceBiotech
Feb 7
Comment
The San Francisco Business Times reports that Corcept Therapeutics execs earned 10% salary hikes after last year's approval of the Cushing's syndrome drug Korlym. CEO Joe Belanoff led the pack with an expanded $530,000 salary, up from $481,097....
Benzinga
Nov 8
Comment
Piper Jaffray reduced its rating on Corcept Therapeutics (NASDAQ: CORT) from Neutral to Underweight and lowered its price target from $3 to $1.10.
Piper Jaffray commented, "We are downgrading Corcept to Underweight from Neutral and cutting our...
Benzinga
Nov 2
Comment
Oppenheimer reduced its rating on Corcept Therapeutics (NASDAQ: CORT) from Outperform to Market Perform.
Oppenheimer commented, "On 10/31 Corcept reported 3Q12 results and provided an update on the commercial launch of Korlym, its European...
StreetInsider.com
Oct 31
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Corcept+Therapeutics%2C+Inc.+%28CORT%29+Tops+Q3+EPS+by+1c/7832291.html for the full story.
Benzinga
Oct 15
Comment
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, announced today that Daniel M....
Benzinga
Sep 13
Comment
Piper Jaffray reduced its rating on Corcept Therapeutics (NASDAQ: CORT) from Overweight to Neutral and lowered its price target from $5 to $3.
Piper Jaffray said, "We are downgrading CORT to Neutral from Overweight and cutting our price target...
StreetInsider.com
Aug 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Corcept+%28CORT%29+Sells+Synthetic+Capped+Royalty+on+Future+Sales+for+%2430M%3B+Terminates+CEFF+with+Kingsbridge/7636535.html for the full story.
StreetInsider.com
Aug 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Corcept+Therapeutics%2C+Inc.+%28CORT%29+Posts+Narrower+than+Expected+Q2+Loss+of+9cShare/7636496.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
